Fetal RhD NIPT: do all Rh negative patients need Rh immune globulin?

RhD Testimonials: Dr. Cazes

The evolution of NIPT: what comes next

In this talk, we will highlight how early, highly accurate prenatal screening optimizes outcomes for patients with 22q11.2 deletion syndrome, and review recently-published data from a large clinical v

Clinical Validation of a SNP-based Prenatal Cell-free DNA Screening Test for Fetal RHD Status in a Large US Cohort

Fetal RhD NIPT: A new testing option to inform care for RhD alloimmunized patients and those at risk

Natera™'s Fetal RhD NIPT (noninvasive prenatal testing) is now available. The test is backed by the largest clinical validation study for fetal RhD in the US to date, and demonstrated 100 percent sens

It's time to screen routinely for 22q11.2 deletion syndrome: new evidence of improved outcomes with prenatal diagnosis

To manage pregnancies at high risk for 22q11.2 deletion syndrome (DS), prenatal and neonatal evaluation after high risk cfDNA screening is needed. Supplemental assessments and early intervention can i

Carrier Manifestations in Pregnancy

Utility of carrier screening to inform management

Introduction to Genetic Counseling Roles in Industry

Genetic Counselor Awareness Day 2023

22q11.2 deletion syndrome

Why to screen for 22q11.2 deletion syndrome during your pregnancy with NIPT.

Low fetal fraction results for clinicians

A guide to discussing a result with low fetal fraction from Panorama NIPT with patients.

Microdeletion syndromes

Why it’s important to screen for microdeletion syndromes during your pregnancy with NIPT.

Atypical finding results for clinicians

A guide to discussing atypical findings from Panorama NIPT with patients

Natera Webinar Series Part III: What’s SMART about screening for sex chromosome trisomies : early intervention matters

Natera Webinar Series Part II: NIPT for 22q11.2 DS: Does evidence support routine screening?

During this webinar series, Natera’s medical leadership team will review publications with significant findings from SNP-based NIPT results.

Natera Webinar Series Part I: Suspected maternal malignancies detected by NIPT: what you need to know - Direct

Review what is known about noninvasive prenatal screening and incidental findings associated with maternal malignancy.

Webinar: Clinical experience with SNP-based NIPT for aneuploidy detection in twins

This webinar will focus on our recent publication in Prenatal Diagnosis — Positive predictive value of a single nucleotide polymorphism (SNP)‐based NIPT for aneuploidy in twins.

Panorama® Patient Overview

Replaced "About the Panorama Prenatal Screen"

Parker's Story

Behind the Bench: PGT from the lab perspective